Another anti-PD-1 agent, pembrolizumab (KEYTRUDA, Merck & Co., Inc.)was approved for advanced melanoma in 2014, followed by several other approvals in other cancer types, such as advanced NSCLC in 2015, Hodgkin lymphoma and urothelial carcinoma in 2017. Here, PDCD1 is linked to melanoma.